2024-10-22 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

This report provides a comprehensive analysis of AbbVie Inc. (ABBV) stock, covering its performance, technical indicators, recent earnings, and current market sentiment.

**1. Performance Overview**

AbbVie Inc. (ABBV) is a global pharmaceutical company that develops, manufactures, and markets a broad range of medicines in various therapeutic areas. 

As of the latest data, ABBV has generated a cumulative return of **145.47%**, outperforming the S&P 500 (VOO) with a cumulative return of **137.88%**. This represents a **7.59%** outperformance relative to the benchmark index. The relative outperformance is currently at the **49.86th percentile** compared to its historical range, indicating a moderately strong performance relative to the market.

**2. Technical Analysis**

* **Closing Price:** $188.86
* **5-Day Moving Average:** $191.08
* **20-Day Moving Average:** $193.61
* **60-Day Moving Average:** $193.03

The stock price is currently below its 5, 20, and 60-day moving averages, suggesting potential downward momentum in the short term. 

**3. Momentum and Valuation Indicators**

* **RSI:** 23.77
* **PPO:** -0.41
* **Delta_Previous_Relative_Divergence:** -11.0 (indicates short-term downward trend)
* **Expected_Return:** 5.45% (represents potential long-term outperformance relative to the S&P 500)

The RSI suggests the stock is oversold, potentially indicating a rebound. However, the negative PPO and Delta_Previous_Relative_Divergence signal short-term bearish sentiment.  The Expected Return of 5.45% suggests potential long-term growth potential, but investors should carefully consider the short-term bearish trends.

**4. Recent Earnings and Outlook**

| Date      | EPS | Expected EPS |
|-----------|-----|--------------|
| 2024-07-25 | 2.65 | 2.57        |
| 2024-04-26 | 2.31 | 2.26        |
| 2024-02-02 | 2.79 | 2.76        |
| 2023-10-27 | 2.95 | 2.86        |
| 2023-07-27 | 2.91 | 2.79        |

AbbVie has consistently beaten analyst earnings expectations over the last few quarters. This suggests a strong financial performance, which might be a positive factor for long-term investors. The most recent earnings report (2024-07-25) showed EPS of $2.65 exceeding the expected EPS of $2.57, further reinforcing the positive performance.

**5. News and Recent Issues**

Recent market outlook for ABBV is positive, with analysts highlighting the strong performance of its key drugs, such as Humira and Rinvoq. The stock has been facing some pressure due to concerns about competition and patent expirations, but analysts are optimistic about its long-term growth prospects. 

**FINBOLD** reports a **Buy** rating for ABBV, emphasizing the company's strong financial position and pipeline of new drugs. Other analysts also highlight the company's focus on innovation and its commitment to R&D as positive factors.

**6. Overall Analysis**

AbbVie Inc. (ABBV) is a well-established pharmaceutical company with a strong track record of performance and earnings growth. The stock has outperformed the S&P 500 in the long term, but short-term technical indicators suggest a potential pullback. Recent earnings have been strong, exceeding analyst expectations, and the company has a robust pipeline of new drugs. Overall, ABBV presents a compelling investment case for long-term investors seeking exposure to the pharmaceutical sector.

**7. Recommendations**

Long-term investors may consider investing in ABBV given its strong financials, consistent earnings growth, and promising long-term prospects. However, investors should monitor the short-term market trends and consider potential risks related to competition and patent expirations. 
